Advertisement

Dose Escalation with Simultaneous Integrated Boost (SIB) Using Volumetric Modulated Arc Therapy (VMAT) in Rectal Cancer

  • Abdullah Alsuhaibani
  • Ahmed Elashwah
  • Rana Mahmood
  • Alaa Abduljabbar
  • Samar Alhomoud
  • Luai Ashari
  • Shouki Bazarbashi
  • Ali Aljubran
  • Ahmed Alzahrani
  • Muhamed Mohiuddin
  • Hadeel Almanea
  • Hussah Alhussaini
  • Nasser AlSanea
Original Research
  • 33 Downloads

Abstract

Purpose

Assess feasibility—rate of PCR, short-term toxicity after neoadjuvant concurrent chemoradiation (NACRT) delivered via simultaneous integrated boost (SIB) using volumetric modulated arc therapy (VMAT) technique for locally advanced rectal cancer.

Methods

Retrospective evaluation of patients with locally advanced rectal cancer treated with VMAT-SIB technique preoperatively at an academic tertiary care center in Riyadh, Saudi Arabia between February 2013 and March 2017.

Results

One hundred patients with depth of invasion staged as T3/T4 or T2 in 93 and seven patients, respectively. Lymph node metastasis was staged as N1/N2 or N0 in 87 and 13 patients, respectively. Circumferential radial margin (CRM) was involved radiologically prior to treatment in 50 patients. A dose of 55 or 50 Gy was given to 71 and 29 patients, respectively. All treatments were completed without interruption. Grade 3/4 toxicity was not observed. Low anterior resection and abdominoperineal resection were performed with negative proximal, distal, and radial margins in 72 and 28 patients, respectively. There were no immediate significant postoperative complications. Histologically, no residual tumor (grade 0) was noted in 20 patients (pCR). Regression grade 1, 2, and 3 were noted in 31, 34, and 15 patients. Average number of lymph nodes retrieved in the surgical specimen was 12 (range 6–22). Lymph nodes were negative for cancer in 80 patients.

Conclusion

Dose escalation with SIB-VMAT as NACRT for rectal cancer is feasible. Moreover, it can increase the rate of pathological complete response with a favorable toxicity profile. Clinical benefit of this approach needs to be validated in a larger cohort of patients with longer follow-up.

Keywords

Rectal Cancer Volumetric modulated arc therapy (VMAT) Radiation Therapy Surgery Chemotherapy Complete Pathology Response Dose Toxicity Patients Simultaneous integrated boost (SIB) 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Glimelius B, Holm T, Blomqvist L. Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer—a systematic overview. Rev Recent Clin Trials. 2008;3:204–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Alsanea N, Abduljabbar AS, Alhomoud S, Ashari LH, Hibbert D, Bazarbashi S. Colorectal cancer in Saudi Arabia: incidence, survival, demographics and implications for national policies. Ann Saudi Med. 2015;35(3):196–202.  https://doi.org/10.5144/0256-4947.2015.196. CrossRefPubMedGoogle Scholar
  3. 3.
    Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44.CrossRefPubMedGoogle Scholar
  5. 5.
    Vecchio FM, Valentini V, Minsky BD, Padula GDA, Venkatraman ES, Balducci M, et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:752–60.CrossRefPubMedGoogle Scholar
  6. 6.
    McCarthy K, Pearson K, Fulton R, et al. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev. 2012;12:CD008368.PubMedGoogle Scholar
  7. 7.
    Sanghera P, Wong DW, McConkey CC, et al. Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol. 2008;20:176–83.CrossRefGoogle Scholar
  8. 8.
    Valentini V, Beets-Tan R, Borras JM, Krivokapić Z, Leer JW, Påhlman L, et al. Evidence and research in rectal cancer. Radiother Oncol. 2008;87:449–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–96.CrossRefPubMedGoogle Scholar
  10. 10.
    Overgaard M, Overgaard J, Sell A. Dose–response relationship for radiation therapy of recurrent, residual, and primarily inoperable colorectal cancer. Radiother Oncol. 1984;1:217–25.CrossRefPubMedGoogle Scholar
  11. 11.
    Gunderson LL, Cohen AM, Welch CE. Residual, inoperable or recurrent colorectal cancer interaction of surgery and radiotherapy. Am J Surg. 1980;139:518–25.CrossRefPubMedGoogle Scholar
  12. 12.
    Gallagher MJ, Breretin HD, Rostock RA, et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys. 1986;12:1565–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Andreyev HJN. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol. 2007;19:790–9.CrossRefGoogle Scholar
  14. 14.
    Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum. 1993;36:564–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Letschert JG, Lebesque JV, de Boer RW, et al. Dose–volume correlation in radiation related late small-bowel complications: a clinical study. Radiother Oncol. 1990;18:307–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Frykholm GJ, Isacsson U, Nygard K, et al. Preoperative radiotherapy in rectal carcinoma—aspects of acute adverse effects and radiation technique. Int J Radiat Oncol Biol Phys. 1996;35:1039–48.CrossRefPubMedGoogle Scholar
  17. 17.
    Olofsen-Van Acht M, van den BH, Quint S, et al. Reduction of irradiated small bowel volume and accurate patient positioning by use of a bellyboard device in pelvic radiotherapy of gynecological cancer patients. Radiother Oncol. 2001;59:87–93.CrossRefPubMedGoogle Scholar
  18. 18.
    Singh AK, Guion P, Sears-Crouse N, Ullman K, Smith S, Albert PS, et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol. 2007;2:36.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Urbano MT, Henrys AJ, Adams EJ, et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys. 2006;65:907–16.CrossRefGoogle Scholar
  20. 20.
    Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys. 2000;46:619–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Menkarios C, Azria D, Laliberté B, Moscardo C, Gourgou S, Lemanski C, et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol. 2007;2:41.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Guerrero M, Li XA, Ma L, Linder J, Deyoung C, Erickson B. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations. Int J Radiat Oncol Biol Phys. 2005;62:933–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Blomqvist L, Rubio C, Holm T, Machado M, Hindmarsh T. Rectal adenocarcinoma: assessment of tumour involvement of the lateral resection margin by MRI of resected specimen. Br J Radiol. 1999;72:18–23.CrossRefPubMedGoogle Scholar
  24. 24.
    Brown G, Davies S, Williams GT, Bourne MW, Newcombe RG, Radcliffe AG, et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer. 2004;91:23–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Marks LB, Ma J. Challenges in the clinical application of advanced technologies to reduce radiation-associated normal tissue injury. Int J Radiat Oncol Biol Phys. 2007;69:4–12.CrossRefPubMedGoogle Scholar
  26. 26.
    Veldeman L, Madani I, Hulstaert F, de Meerleer G, Mareel M, de Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol. 2008;9:367–75.CrossRefPubMedGoogle Scholar
  27. 27.
    Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol. 2010;22:643–57.CrossRefGoogle Scholar
  28. 28.
    RTOG protocol 0022. Phase I/II study of conformal and intensity modulated irradiation for oropharyngeal cancer. http://www.rtog.org.members/protocols/h0022/h0022.pdf.
  29. 29.
    Dogan N, King S, Emami B, Mohideen N, Mirkovic N, Leybovich LB, et al. Assessment of different IMRT boost delivery methods on target coverage and normal tissue sparing. Int J Radiat Oncol Biol Phys. 2003;57:1480–91.CrossRefPubMedGoogle Scholar
  30. 30.
    Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32(15):1554–62.  https://doi.org/10.1200/JCO.2013.54.3769.CrossRefPubMedGoogle Scholar
  31. 31.
    Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835e844.CrossRefGoogle Scholar
  32. 32.
    Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol. 2001 Apr;24(2):107–12.CrossRefPubMedGoogle Scholar
  33. 33.
    Al Zahrani A, Mohammed M, Ashari L, et al. Response to neoadjuvant CHEMORADIATION in rectal cancer: time to consider risk-adapted adjuvant chemotherapy. Ann Oncol. 2013;24(suppl 4):iv86–7.  https://doi.org/10.1093/annonc/mdt203.176.CrossRefGoogle Scholar
  34. 34.
    Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638–44.CrossRefPubMedGoogle Scholar
  35. 35.
    Bourhis J, Sire C, Lapeyre M, et al. Accelerated radiotherapy and/or concomitant chemotherapy in locally advanced head and neck SCC: results of a GORTEC randomized trial. Radiother Oncol. 2008;88(2):S121.Google Scholar
  36. 36.
    Aschele C, Pinto C, Cordio S, et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol. 2009;27:170s. (suppl; abstr CRA4008)CrossRefGoogle Scholar
  37. 37.
    Wong R, Thomas G, Cummings B, Froud P, Shelley W, Withers R, et al. In search of a dose–response relationship with radiotherapy in the management of recurrent rectal carcinoma in the pelvis: a systematic review. Int J Radiat Oncol Biol Phys. 1998;40:437–46.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Abdullah Alsuhaibani
    • 1
  • Ahmed Elashwah
    • 2
    • 3
  • Rana Mahmood
    • 2
  • Alaa Abduljabbar
    • 4
  • Samar Alhomoud
    • 4
  • Luai Ashari
    • 4
  • Shouki Bazarbashi
    • 5
  • Ali Aljubran
    • 5
  • Ahmed Alzahrani
    • 5
  • Muhamed Mohiuddin
    • 2
  • Hadeel Almanea
    • 6
  • Hussah Alhussaini
    • 6
  • Nasser AlSanea
    • 4
  1. 1.Oncology Center ,University Medical CityKing Saud UniversityRiyadhSaudi Arabia
  2. 2.Section of Radiation OncologyKing Faisal Specialist Hospital & Research CentreRiyadhSaudi Arabia
  3. 3.Kasr Al-Eini Center of Clinical Oncology (NEMROCK)Cairo UniversityCairoEgypt
  4. 4.Section of Colon and Rectal SurgeryKing Faisal Specialist Hospital & Research CentreRiyadhSaudi Arabia
  5. 5.Section of Medical OncologyKing Faisal Specialist Hospital & Research CentreRiyadhSaudi Arabia
  6. 6.Pathology and Laboratory MedicineKing Faisal Specialist Hospital & Research CentreRiyadhSaudi Arabia

Personalised recommendations